[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556244":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":40,"responsibleParty":56,"collaborators":37,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":37,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":37,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":37,"overallStatus":43,"whyStopped":37,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Armed Forces Hospital, Pakistan","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"neonates with HIE receiving citicoline","EXPERIMENTAL","this arm will include neonates suffering from hypoxic ischemic encephalopathy and who will be given injection citicoline",[13],"Drug: Citicoline Sodium",{"label":15,"type":16,"description":17,"interventionNames":18},"neonates with HIE receiving placebo","PLACEBO_COMPARATOR","this arm will include neonates who will be suffering from HIE but will recieve rotuine care in NICU but will not receive injection citicoline",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Citicoline Sodium","one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth",[9,15],[26],"placebo",[28],{"name":29,"affiliation":30,"role":31},"arshad Khushdil, FCPS","PEMH","PRINCIPAL_INVESTIGATOR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"arshad Khushdil","CONTACT","03463300030",null,"drarshad104589@yahoo.com",{"name":34,"role":35,"phone":36,"phoneExt":37,"email":37},[41],{"facility":42,"status":43,"city":44,"state":37,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"MH","RECRUITING","Rawalpindi","68000","Pakistan","PK",{"type":49,"coordinates":50},"Point",[51,52],73.0479,33.59733,{"lat":52,"lon":51},[55],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},{"type":31,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"arshad khushdil","Doctor","100556244","phase-1-role-of-citicoline-in-treatment-of-neonates-with-hypoxic-ischemic-encephalopathy-100556244",false,"NCT06522581","Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy","Inclusion Criteria:\n\n1. all indoor newborn babies with HIE II and III\n2. who have not received therapeutic hypothermia\n\nExclusion Criteria:\n\n1. grade I HIE\n2. Babies on TH\n3. babies whose parents do not give consent for inclusion in study\n4. babies with major congential malformations -","ALL","1 Day","30 Days",{"count":69,"type":70},200,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births.\n\nInfants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.",[76],"Hypoxic Ischemic Encephalopathy of Newborn","2024-08-12",{"date":79,"type":80},"2024-08-14","ACTUAL",{"date":82,"type":80},"2024-01-01",{"date":84,"type":70},"2025-01-01",{"name":5,"class":6},1]